Skip to main content

Table 2 Mean values (±SD) of clinical outcomes measure after RAGT ± VR. Within- and between-group comparisons, with confidence interval (95%) (CI), are reported. Not reported data are non-significant

From: The role of virtual reality in improving motor performance as revealed by EEG: a randomized clinical trial

parameter Group PRE POST Within-group Between-group CI (95%)
RMI RAGT + VR 8 ± 1 14 ± 1 <0.001 0.001 1.2 to 7.6
RAGT-VR 7 ± 1 9 ± 1 0.01
POMA RAGT + VR 17 ± 3 23 ± 3 0.001 0.01 1.2 to 7.6
RAGT-VR 12 ± 4 15 ± 4  
MAS RAGT + VR 2 ± 0.5 2 ± 0.5    
RAGT-VR 2 ± 0.5 2 ± 0.5  
HRS RAGT + VR 11 ± 3 7 ± 3 0.01   
RAGT-VR 13 ± 3 10 ± 3 0.02
VAS RAGT + VR 6 ± 1 8 ± 1 <0.001 0.01 1.3 to 15.3
RAGT-VR 5 ± 1 6 ± 1  
drowsiness episodes RAGT + VR 5 ± 1 2 ± 1 <0.001 0.009 1 to 6.9
RAGT-VR 5 ± 1 5 ± 1  
Hip force RAGT + VR 36 ± 7 42 ± 3 0.01 0.02 −6.2 to −3.8
RAGT-VR 34 ± 6 38 ± 10  
Knee force RAGT + VR 31 ± 8 47 ± 6 <0.001 0.02  
RAGT-VR 30 ± 7 36 ± 3 0.04
  1. Legend: RMI Rivermead Mobility Index; POMA Tinetti Performance Oriented Mobility Assessment; MAS Modified Ashwort Scale; HRS Hamilton Rating Scale for depression; VAS visual analogic scale